DLX6 and hepatocellular carcinoma: DLX6-AS1 inhibits ANXA10 expression through ubiquitination-mediated degradation to accelerate hepatocellular carcinoma development, which can be attributed to the regulation on miR-513c/Cul4A axis [25].